You are here: Welcome » Kyla Hildebrand

This is an old revision of the document!


Kyla Hildebrand

Dr. Kyla Hildebrand is a Canadian allergist and clinical immunologist based in Vancouver, British Columbia. She is notable in the COVID-19 pandemic for her role in approving COVID-19 vaccines on the National Advisory Committee on Immunization (NACI).

Education

Hildebrand completed medical school at the University of Manitoba in 2005, Pediatrics Residency at the University of Alberta, and a fellowship in Clinical Immunology and Allergy at the University of Toronto.1) 2) She completed a Master of Science in Community Health at the University of Toronto and was the 2010 recipient of the Royal College of Physicians and Surgeons of Canada Fellowship for Studies in Medical Education.

Affiliations

Hildebrand began her academic career at the University of Western Ontario.

Hildebrand is a researcher at the BC Children's Hospital Research Institute.3) She is also a clinical associate professor in the Division of Allergy and Immunology, Department of Pediatrics, Faculty of Medicine, at the University of British Columbia.4)

Hildebrand sits on the board of directors for the Canadian Society of Allergy and Clinical Immunology (CSACI), and has received honoraria from the BC Society of Allergy and Immunology (BCSAI).5) 6)

1)
Hildebrand, Kyla Jade - Doctor Details. (2013, June 3). College of Physicians and Surgeons of Ontario. https://archive.ph/b2elA
2)
Kyla Hildebrand - Clinical Assistant Professor of Pediatrics Allergy and Immunology in Vancouver, British Columbia, Canada. eMedEvents. Retrieved April 18, 2022, from https://web.archive.org/web/20220418074053/https://www.emedevents.com/speaker-profile/kyla-hildebrand
3)
Kyla Hildebrand. BC Children’s Hospital Research Institute. Retrieved April 17, 2022, from https://www.bcchr.ca/khildebrand
4)
Welcome to Dr. Kyla Hildebrand | Department of Pediatrics. (2013, September 3). University of British Columbia. https://archive.ph/BMCDk
5)
Li, L. D. X., Abrams, E. M., Lavine, E., Hildebrand, K., & Mack, D. P. (2021). CSACI position statement: transition recommendations on existing epinephrine autoinjectors. Allergy, Asthma & Clinical Immunology, 17(1). https://doi.org/10.1186/s13223-021-00634-2
6)
Program Directors. Canadian Society of Allergy and Clinical Immunology. Retrieved April 18, 2022, from https://web.archive.org/web/20220418180939/https://www.csaci.ca/program-directors/
Back to top